Tigecycline



Tigecycline





(tye gah sigh’ klin)

Tygacil

PREGNANCY CATEGORY D


Drug Classes

Antibiotic

Glycylcycline


Therapeutic Actions

Inhibits protein translation on ribosomes in specific bacteria, leading to inhibition of bacterial cell growth and cell death; mechanism is not used by many resistant strains.


Indications



  • Treatment of complicated skin and skin structure infections caused by susceptible strains of Escherichia coli, Enterococcus faecalis (vancomycin-susceptible strains only), Staphylococcus aureus (methicillin-susceptible and resistant strains), Streptococcus agalactiae, Streptococcus anginosus, Streptococcus pyogenes, Bacteroides fragilis, Klebsiella pneumoniae, Enterobacter cloacae


  • Treatment of adults with community-acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae, Legionella pneumophila


  • Treatment of intra-abdominal infections caused by Citrobacter freundii, Enterobacter cloacae, E. coli, Klebsiella oxytoca, Klebiella pneumoniae, Enteroccus faecalis (vancomycin susceptible strains only), S. anginosus, B. fragilis, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Clostridium perfringens, Peptostreptococcus micros


  • Unlabeled use: Hospital-acquired pneumonia



Available Forms

Powder for reconstitution for injection—50 mg/5 mL vial


Dosages

Adults

100 mg IV, followed by 50 mg IV every 12 hr. Tygacil should be infused over 30–60 min. Therapy should continue for 5–14 days, based on patient response and bacterial progress.

Patients with severe hepatic impairment (Child-Pugh C)

100 mg IV, followed by 25 mg IV every 12 hr. Patient should be monitored closely.

Jul 21, 2016 | Posted by in NURSING | Comments Off on Tigecycline

Full access? Get Clinical Tree

Get Clinical Tree app for offline access